Item 8.01 Other Events.

On January 26, 2021, Agios Pharmaceuticals, Inc. issued a press release announcing that its global phase 3 ACTIVATE-T trial of mitapivat in adults with pyruvate kinase deficiency who are regularly transfused met its primary endpoint. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
  No.       Description

99.1          Press release issued January 26, 2021.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses